Verona Pharma
plc
("Verona Pharma" or the
"Company")
Verona to present
clinical data on RPL554 at the ATS International Conference
04 May 2016, Cardiff – Verona Pharma plc (AIM: VRP.L),
the drug development company focused on first-in-class medicines to
treat respiratory diseases, today announces that it will present
three abstracts at the American Thoracic Society (ATS) 2016
International Conference in San
Francisco, USA between
13-18 May. The abstracts will cover clinical data related to the
Company’s lead drug RPL554, a novel inhaled PDE3/PDE4 inhibitor
with both bronchodilator and anti-inflammatory properties,
currently in development as a nebulised treatment for acute
exacerbations in chronic obstructive pulmonary disease (COPD)
patients in a hospital or home-care setting.
All three posters support Verona Pharma’s view that RPL554 could
become an important, novel and complementary inhaled medicine for
the treatment of respiratory diseases such as COPD, asthma, and
cystic fibrosis.
All abstracts and details on timings can be accessed through the
ATS website: http://conference.thoracic.org/
The title, timing and location of the poster presentations are
as follows:
Abstract |
ID 13130 |
Authors: |
L. Bjermer, J. Stewart, K.
Abbott-Banner, K. Newman |
Title: |
RPL554, a First-In-Class Dual
Phosphodiesterase (PDE)3/4 Inhibitor, Is Equi-Effective as a
Bronchodilator to Maximal Doses of Salbutamol in Asthmatics but
with Fewer Adverse Events |
Day/Date: |
SUNDAY, MAY 15, 2016 |
Location: |
Area A (Hall D) Moscone Centre
(North Building) P36 |
Time: |
9:00 AM-4:15 PM |
Session: |
A31 - ASTHMA THERAPY:
GLUCOCORTICOIDS AND BEYOND |
Session Type: |
Thematic Poster Session |
Abstract |
ID 6811 |
Authors: |
D. Singh, K.H. Abbott-Banner, F.
Reid, K. Newman |
Title: |
A Phase I, Randomised, Double Blind,
Placebo Controlled, Study To Assess The Safety, Tolerability And
Pharmacokinetics Of Multiple Inhaled Doses Of RPL554 Administered
By Nebuliser To Healthy Male Subjects And Stable COPD Patients |
Day/Date: |
WEDNESDAY, MAY 18, 2016 |
Location: |
Area A (Hall D) Moscone Centre
(North Building) P71 |
Time: |
9:00 AM-3:30 PM |
Session: |
D37-COPD: DEVELOPMENTAL
THERAPEUTICS |
Session Type: |
Thematic Poster Session |
Abstract |
ID 4841 |
Authors: |
D. Singh, K.H. Abbott-Banner, F.
Reid, K. Newman |
Title: |
A Phase I, Randomised, Double Blind,
Placebo Controlled, Study To Assess The Safety, Tolerability And
Pharmacokinetics Of Single Inhaled Doses Of The Dual
Phosphodiesterase 3/4 (PDE3/4) Inhibitor RPL554 Administered By
Nebuliser To Healthy Male subjects |
Day/Date: |
WEDNESDAY, MAY 18, 2016 |
Location: |
Area A (Hall D) Moscone Centre
(North Building) P72 |
Time: |
9:00 AM-3:30 PM |
Session: |
D37-COPD: DEVELOPMENTAL
THERAPEUTICS |
Session Type: |
Thematic Poster Session |
-ENDS-
About Verona Pharma
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase 2 trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for COPD
and asthma maintenance therapy. In addition, the Company is
exploring the potential of the drug in different diseases, such as
cystic fibrosis, where it is in pre-clinical testing and has
received a Venture and Innovation Award from the UK Cystic Fibrosis
Trust.
About ATS International Conference
The ATS International Conference is the home of pulmonary,
critical care, and sleep professionals, from those in the earliest
stages of their careers to people with research or strides in
clinical care, which has gained them international recognition.
Each year, nearly 14,000 of these professionals choose to attend,
present, and learn about the latest advances, meet with colleagues
from around the world, and strike new collaborations. It is truly
where today’s science meets tomorrow’s care.
The International Conference is also multidisciplinary.
Clinicians and researchers in many other fields attend the
conference, thereby enriching conversations that lead to insights
that ultimately improve patient care. Among the many other
specialties represented in sessions at the International Conference
are:
Allergy/Immunology, Behavioural Science, Cardiology,
Environmental and Occupational Health, Infectious Disease,
Paediatric, Pulmonary, Critical Care and Sleep
Equally important, the ATS International Conference gathers the
entire health care team in one place to share ideas across these
medical and scientific disciplines. It is the ideal place for
nurses, respiratory therapists, and hospitalists to discuss their
experiences, challenges, and research so that all can learn about
the latest advances in understanding pulmonary disease, critical
illness, and sleep disorders. And of course, the International
Conference is truly international: 40 percent of attendees arrive
from laboratories and patient care centres beyond the United States.
Further information on the conference can be accessed via the
following weblink: http://conference.thoracic.org/
For further information, please
contact:
Verona Pharma plc |
Tel: +44 (0) 20 7863
3300 |
Jan-Anders Karlsson, CEO |
|
N+1 Singer |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen
Boorer |
|
FTI Consulting |
Tel: +44 (0)20 3727 1000 |
Simon Conway / Stephanie Cuthbert/
Natalie Garland-Collins |
|